Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14993530 | 0.94 | MEN1 (0.49) | MEN1KMT2ASIRT6TDP1ALDH1A1 | |
| SCHEMBL2062118 | 0.84 | KMT2A (0.58) | MEN1KMT2ASIRT6TDP1ALDH1A1 | |
| SCHEMBL11923833 | 0.81 | MEN1 (0.70) | MEN1KMT2AALDH1A1LRRK2CYP3A4 | |
| SCHEMBL30242551 | 0.81 | MEN1 (0.69) | MEN1KMT2ASIRT6TDP1ALDH1A1 | |
| SCHEMBL2205991 | 0.81 | MEN1 (0.69) | MEN1KMT2ASIRT6TDP1ALDH1A1 | |
| SCHEMBL14993476 | 0.79 | LRRK2 (0.42) | ALDH1A1LMNALRRK2KDM4ECYP3A4 | |
| SCHEMBL20214438 | 0.79 | KMT2A (0.58) | MEN1KMT2ASIRT6TDP1ALDH1A1 | |
| SCHEMBL14993936 | 0.77 | SIRT6 (0.55) | SIRT6TDP1ALDH1A1LMNARAB9A | |
| SCHEMBL15339545 | 0.77 | KMT2A (0.55) | MEN1KMT2ATDP1ALDH1A1LMNA | |
| SCHEMBL25637679 | 0.76 | TDP1 (0.38) | MEN1KMT2ASIRT6TDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2785709-B1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH INC (US) | 2017-05-10 | — | — | EP | disclosed |
| EP-2785709-B1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH INC (US) | 2017-05-10 | — | — | EP | disclosed |
| EP-3121173-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2017-01-25 | — | — | EP | disclosed |
| EP-3121173-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2017-01-25 | — | — | EP | disclosed |
| EP-2785709-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-10-08 | — | — | EP | disclosed |
| US-8796296-B2 | Aminopyrimidine derivatives as LRRK2 modulators | GENENTECH, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796296-B2 | Aminopyrimidine derivatives as LRRK2 modulators | GENENTECH, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796296-B2 | Aminopyrimidine derivatives as LRRK2 modulators | GENENTECH, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20130158006-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158006-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158006-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| WO-2013079505-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-06 | — | — | WO | disclosed |
| WO-2013079505-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158006-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | LRRK2, PARK7, PINK1 | MEN1 4534/4885KMT2A 1509/4885SIRT6 1065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.